Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corporation (TWST), reported a sale on 09/08/2025. The Form 4 shows a non-discretionary sell-to-cover transaction of 269 shares of common stock at $25.76 per share to satisfy tax withholding obligations arising from Restricted Stock Unit vesting. Following the transaction, the reporting person beneficially owns 103,037 shares directly. The filing was signed by an attorney-in-fact on behalf of the reporting person on 09/10/2025.
Twist Bioscience insider sale to cover taxes; reporting confirms compliance. The filing shows Paula Green, SVP of Human Resources and a company officer, had 892 shares sold on 09/08/2025 at $25.76 per share to satisfy tax-withholding obligations arising from the vesting of Restricted Stock Units. After the transaction, the reporting person beneficially owned 124,837 shares, held directly. The sale is described as a mandatory "sell-to-cover" under the issuer's equity plan and therefore is not a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/10/2025.
Emily M. Leproust, CEO and Director of Twist Bioscience (TWST), reported a routine insider transaction. The filing shows a sale of 2,265 shares of Twist common stock on 09/08/2025 at $25.76 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units; these sales were mandated by the issuer's sell-to-cover election and are not discretionary trades. After the sale, the reporting person beneficially owns 634,740 shares. The form also lists outstanding employee stock options at various exercise prices and vesting schedules, including exercisable options with a $67.85 strike covering 64,950 shares.
Insider sale linked to tax-withholding for vested RSUs. Twist Bioscience Corp reporting person Robert F. Werner, listed as Chief Accounting Officer, recorded a sale on 09/08/2025. The Form 4 shows a sale of 235 shares of common stock at a price of $25.76 per share, leaving the reporting person with 48,454 shares beneficially owned, held directly.
The filing explains the sale represents shares required to be sold to satisfy tax withholding obligations related to the vesting of restricted stock units and was a company-mandated "sell to cover" rather than a discretionary trade. The form was signed by an attorney-in-fact on 09/10/2025.
Twist Bioscience (TWST) filed a Form 144 reporting a proposed insider sale of common stock and recent related transactions. The notice shows 269 shares that vested as restricted stock on 09/05/2025 and are planned for sale on 09/08/2025 through Fidelity Brokerage Services (NASDAQ). The filing lists an aggregate market value for the 269 shares of $6,929.41 and identifies the payment as compensation for the vesting. The filer also reported five open-market sales by the same person over the prior three months totaling 1,755 shares for gross proceeds of $51,687.54. The filer certifies no undisclosed material information.
Form 144 filed for Twist Bioscience (TWST) reports a proposed sale of 2,265 common shares through Fidelity Brokerage Services with an aggregate market value of $58,346.17 and an approximate sale date of 09/08/2025 on NASDAQ. The shares were acquired on 09/05/2025 through restricted stock vesting from the issuer and payment was recorded as compensation. The filer has sold 10,455 common shares in the past three months across four transactions (06/20/2025: 1,678; 07/02/2025: 476; 08/04/2025: 5,585; 08/21/2025: 2,716) generating gross proceeds of $300,156.58. Outstanding shares listed are 60,360,925. The filer affirms no undisclosed material adverse information and the notice includes the statutory signature/representation language.
Form 144 notice from Robert Werner regarding Twist Bioscience (TWST)
The filing reports a proposed public sale of 235 shares of TWST common stock through Fidelity Brokerage Services with an approximate aggregate market value of $6,053.58, slated for 09/08/2025. Those 235 shares were acquired via restricted stock vesting on 09/05/2025 and paid as compensation. The filing lists TWST’s shares outstanding as 60,360,925. The filer also disclosed sales during the prior three months totaling 1,277 shares on 08/04, 08/21 and 08/25 with combined gross proceeds of $34,075.88. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
The filing is a Form 144 notice for Twist Bioscience Corporation (TWST) reporting a proposed sale of 892 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $22,977.83 and an approximate sale date of 09/08/2025. The shares were acquired on 09/05/2025 by restricted stock vesting and paid as compensation. The filer discloses four prior sales by the same person between 06/20/2025 and 08/21/2025, totaling 2,308 shares with combined gross proceeds shown. The notice includes the required statement that the seller is not aware of undisclosed material adverse information.
Robert F. Werner, Chief Accounting Officer and director of Twist Bioscience Corp (TWST), reported a non-discretionary sale of 853 shares of common stock on 08/25/2025 at a price of $27.691 per share to satisfy tax withholding obligations related to vested restricted stock units. After the transaction, Mr. Werner beneficially owned 48,689 shares directly. The Form 4 was executed by an attorney-in-fact and dated 08/27/2025.
This filing indicates a routine "sell-to-cover" transaction mandated by the issuer to meet tax obligations on vesting and does not represent a voluntary market sale by the reporting person. The disclosure follows Section 16 reporting requirements and shows continued ownership of a material stake by the reporting officer.
The Form 4 shows that Emily M. Leproust, Twist Bioscience Corp (TWST) CEO and director, reported a sale of 2,716 shares of TWST common stock on 08/21/2025 at $25.964 per share to satisfy tax-withholding obligations tied to vested restricted stock units; the filing states these were "sell to cover" transactions required by the issuer and not discretionary trades. After the transaction, Leproust beneficially owned 637,005 shares. The filing also discloses outstanding employee stock options with various exercise prices and exercisable/expiration details, including options exercisable immediately at $5.95, $8.82, $26.66 and $23.33 and a $67.85 option with 64,950 underlying shares exercisable through 08/31/2030.